MedTrace Logo

MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma

NCT02631239 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2021-08-25

No results posted yet for this study

Summary

Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct and heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for 5%\~10%. The frequency of ENKTL among NHL patients is significantly higher in Asia than in Western countries, with poor prognosis. Radiotherapy plus chemotherapy has improved the survival for these patients. But the optimal treatment schedule is controversial. The previous protocols usually contained high dose methotrexate, but the application of them is limited for the toxicity.

Conditions

  • Extranodal NK/T-cell Lymphoma, Nasal Type

Interventions

DRUG

Methotrexate

1g/m2/d IV \*1d

DRUG

Etoposide

200mg/d PO \*3d

DRUG

Dexamethasone

40mg/d PO \*3d

DRUG

Pegaspargase

2500IU/m2/d IM \*1d

RADIATION

Radiotherapy

50-56Gy

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Weili Zhao, Prof · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-16
Primary Completion
2021-03-05
Completion
2022-07-17

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02631239 on ClinicalTrials.gov